The ‘A Vision for Lupus’ initiative aims to highlight current gaps and inconsistencies in lupus care and a vision for improving the future for the estimated five million people1 living with this chronic, inflammatory autoimmune disease.
In March 2018, GSK convened a Global Multidisciplinary Steering Committee comprising a person with lupus, a patient advocacy expert, representation from international lupus patient organisations and clinicians specialising in the condition to discuss how to tackle these barriers and propose patient-centred calls to action to change the future of lupus care.
Although progress has been made in the management of lupus in recent years, the Global Multidisciplinary Steering Committee identified that at a global level, the following challenges still exist:
The ‘A Vision for Lupus’ report highlights three important calls to action to address these challenges:
Systemic Lupus Erythematosus (SLE), or lupus, is a chronic, inflammatory autoimmune disease which affects approximately five million people globally.1,2 In people with SLE, the body produces antibodies that attack its own healthy cells and tissues in addition to producing antibodies to protect against infection.1,3
Over time, lupus can affect many different organs or tissues of the body. Symptoms can vary greatly; some of the most common symptoms of lupus are painful or swollen joints (arthritis), extreme fatigue, skin rashes, anaemia and kidney problems.2
GSK conceived, developed and led this initiative with the input of a Global Multidisciplinary Steering Committee who received a fee for their services.
Job code: NP-GBL-LPU-WCNT-190004
Date of prep: November 2019
A GSK initiative